<DOC>
	<DOCNO>NCT02579005</DOCNO>
	<brief_summary>This project assess feasibility treat advanced cancer use immune system , without anti-cancer drug . In pilot study , investigator propose combine low-dose radiotherapy , lung cancer patient , allogeneic immune cell obtain donor . The patient receive radiotherapy direct one patient 's tumor , well immunomodulatory drug call cyclophosphamide . Thereafter , receive infusion donor immune cell .</brief_summary>
	<brief_title>Radio-Immuno-Modulation Lung Cancer</brief_title>
	<detailed_description>Metastatic lung cancer remain incurable despite numerous study treatment try , include chemotherapy , recently , targeted therapy . Cancer escape immune surveillance different mechanism : low level tumor associate antigen ( TAA ) , regulatory T cell , immunosuppressive cytokine . Non-cytolytic dos radiation show reverse pathway experimental model . It up-regulated density MHC molecules present TAA increase T cell infiltration tumor ( 1 ) . Patients lymphoma , liver prostate cancer treat radiotherapy combine immunotherapy , form TLR9 agonist , autologous dendritic cell prostate-specific antigen vaccine ( 2 , 3 , 4 ) . These trial show induction T cell reactivity TAA . Another form immunotherapy , use patient refractory hematologic malignancy allogeneic hematopoietic stem cell transplantation ( HSCT ) ( 5 ) . Its success rely cell infusion donor , demonstrate immunologic control sustain allogeneic cell ( 6 ) . The approach investigate study us immune cell donor induce tumor destruction reaction . This amplified immunological effect radiotherapy . Many oncogene present lung cancer low-dose radiation increase expression surface tumor cell . In addition , radiation property stimulate production inflammatory cytokine chemokines irradiate site . Finally , donor 's immune cell shall respond physiologically migrate site inflammation . This trigger immune reaction direct abnormal cancer cell . A total 24 patient expect recruited study period , estimate 3 year . The allogeneic cell obtain one two possible donor type . For patient live donor , immune cell harvest collection procedure call leukapheresis . The living donor sibling 6/6 HLA compatibility patient , A , B DRB1 locus . For patient live donor , allogeneic cell cryopreserved umbilical cord blood ( UCB ) unit use . The treatment course follow : 15 Gy radiotherapy deliver single tumor site , could either primary tumor one metastases . Low-dose cyclophosphamide give decrease regulatory T cell activity increase anti-tumor response . Allogeneic immune cell administer thereafter , accord treatment arm patient assign . The global method , result combination procedure describe , patent pending .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Inclusion criterion : Advanced lung cancer document histopathological analysis ; Patients receive least one line anti neoplastic therapy ; Presence least one tumor mass &gt; 1 cm previously irradiate ; Metastases situate one follow site : lung , skeleton , lymph node soft tissue ; Life expectancy great 3 month ; ECOG performance status â‰¤ 2 . Exclusion criterion : Second active cancer necessitate treatment ; History autoimmune disease ; Patients need immunosuppressive medication , include corticosteroid , equivalent dos &gt; 10 mg Prednisone per day ; Decreased diffusion capacity 40 % ; Patients need urgent radiotherapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Radiation</keyword>
	<keyword>Immune response</keyword>
	<keyword>Anti-tumor</keyword>
	<keyword>Lung Cancer</keyword>
</DOC>